Dynavax Technologies Co. (NASDAQ:DVAX) Shares Sold by Legal & General Group Plc

Legal & General Group Plc reduced its position in Dynavax Technologies Co. (NASDAQ:DVAX) by 5.9% during the 4th quarter, HoldingsChannel.com reports. The firm owned 346,310 shares of the biopharmaceutical company’s stock after selling 21,711 shares during the quarter. Legal & General Group Plc’s holdings in Dynavax Technologies were worth $4,422,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the company. Russell Investments Group Ltd. lifted its position in Dynavax Technologies by 96.5% during the fourth quarter. Russell Investments Group Ltd. now owns 2,381 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 1,169 shares in the last quarter. Smartleaf Asset Management LLC lifted its holdings in shares of Dynavax Technologies by 463.3% during the 4th quarter. Smartleaf Asset Management LLC now owns 2,473 shares of the biopharmaceutical company’s stock valued at $32,000 after acquiring an additional 2,034 shares in the last quarter. GAMMA Investing LLC lifted its holdings in shares of Dynavax Technologies by 55.1% during the 4th quarter. GAMMA Investing LLC now owns 4,102 shares of the biopharmaceutical company’s stock valued at $52,000 after acquiring an additional 1,457 shares in the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors purchased a new stake in Dynavax Technologies during the 4th quarter worth $71,000. Finally, Nisa Investment Advisors LLC increased its holdings in Dynavax Technologies by 19.8% in the 4th quarter. Nisa Investment Advisors LLC now owns 6,517 shares of the biopharmaceutical company’s stock valued at $83,000 after purchasing an additional 1,076 shares in the last quarter. Hedge funds and other institutional investors own 96.96% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on the company. HC Wainwright reiterated a “buy” rating and issued a $31.00 target price on shares of Dynavax Technologies in a research note on Friday, February 21st. William Blair reiterated an “outperform” rating on shares of Dynavax Technologies in a research note on Friday, February 21st. StockNews.com raised shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a research report on Monday, February 24th. Finally, The Goldman Sachs Group dropped their price target on shares of Dynavax Technologies from $12.00 to $10.00 and set a “sell” rating on the stock in a research note on Thursday, April 17th.

Dynavax Technologies Stock Performance

Dynavax Technologies stock opened at $10.44 on Tuesday. Dynavax Technologies Co. has a 52 week low of $9.74 and a 52 week high of $14.63. The company has a current ratio of 13.23, a quick ratio of 12.34 and a debt-to-equity ratio of 0.33. The stock has a market cap of $1.30 billion, a P/E ratio of 58.00 and a beta of 1.26. The stock has a 50 day moving average of $12.94 and a 200-day moving average of $12.57.

Dynavax Technologies (NASDAQ:DVAX) last announced its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported $0.05 earnings per share for the quarter, hitting the consensus estimate of $0.05. The company had revenue of $72.03 million during the quarter, compared to analyst estimates of $72.70 million. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. On average, analysts expect that Dynavax Technologies Co. will post 0.32 EPS for the current fiscal year.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.